Asarina Pharma AB (publ)

As of June 30, 2022, Asarina Pharma AB (publ) has 22.64M shares outstanding.

These figures are as of June 30, 2022.

As of June 30, 2022, Asarina Pharma AB (publ) maintains a current ratio of 10.64, meaning it holds 10.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2022. Return on assets (ROA) is negative at -53.91, reflecting losses generated across the asset base.

As of the close on October 1, 2024, Asarina Pharma AB (publ)'s stock has declined approximately 96.92% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.68.

These figures cover the twelve months ended June 30, 2022. Free cash flow yield is negative at -89.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.49, meaning Asarina Pharma AB (publ) raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2022, Asarina Pharma AB (publ) has an Altman Z-Score of -12.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.